PENTIXAPHARM HLDG competitors & alternatives

Similar pharmaceuticals company

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.

radiopharma rival LantheusBiotechnology & Pharmaceuticals

69% match

Biotechnology & Pharmaceuticals

Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.

Similar pharmaceuticals company

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.

Similar pharmaceuticals company

Advanced Accelerator Applications (AAA) is a French pharmaceutical company focused on molecular nuclear medicine, developing and manufacturing radiopharmaceuticals for diagnosis and targeted cancer treatment. Its products include Lutathera and diagnostic agents such as NETSPOT, serving oncology and nuclear-medicine clinicians and patients; AAA was acquired by Novartis in 2018.

Biotechnology & Pharmaceuticals

Cancer Research Horizons is a specialist drug discovery, development, and commercialisation company that translates lab-bench innovations into diagnostics and treatments for cancer patients. The company collaborates with researchers, partners, and investors to advance oncology therapeutics, manage start-ups, and license research tools and data portfolios.

Roche Holding AG1ROG · PharmaceuticalsChina

62% matchPublic

Similar pharmaceuticals company

Roche Holding AG is a healthcare company that develops and provides pharmaceuticals and diagnostic solutions to prevent, diagnose, and treat various diseases. The company primarily focuses on areas such as oncology, immunology, ophthalmology, infectious diseases, and neurological conditions, serving patients, healthcare professionals, and health systems globally.

Radiopharm Theranostics LtdRADX · BiotechCarlton, Australia

71% matchPublic

Biotech

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

ITM Isotope Technologies Munich SEBiotechnologyGermany

69% match

Biotechnology

ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company based in Garching bei München, Germany. It develops, produces, and globally supplies targeted radiotherapeutic and diagnostic agents for cancer treatment. The company notably secured a major €255 million investment round to further advance its clinical pipeline.

Healthcare

PD Theranostics, Inc. (operating as United Theranostics) provides molecular imaging and precision radiopharmaceutical therapy for cancer patients, specializing in treatments for prostate cancer, neuroendocrine tumors, and thyroid cancer. The company utilizes advanced diagnostics such as PET and SPECT scans combined with targeted radiopharmaceuticals to deliver personalized, outpatient treatment plans. Additionally, they participate in clinical trials and collaborate with referring providers to offer innovative cancer care options.

Newrite MedicalMedical Technology

65% match

Medical Technology

Newrite Medical is a developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company provides radiopharmaceutical development, isotope production, and radioligand therapy technologies.

AVACTA GROUP PLCAVCT · BiotechAtlanta, United Kingdom

63% matchPublic

Biotech

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.

Biotech

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.